Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs PIRFENIDONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Pirfenidone is a pyridone derivative that inhibits TGF-β1-mediated collagen synthesis, reduces fibroblast proliferation, and downregulates the production of pro-inflammatory cytokines (e.g., TNF-α, IL-1β) and growth factors. Its exact mechanism in idiopathic pulmonary fibrosis (IPF) is not fully elucidated, but it is thought to exert antifibrotic and anti-inflammatory effects.
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Idiopathic pulmonary fibrosis (IPF)
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
801 mg orally three times daily with food, total daily dose 2403 mg. Starting dose: 267 mg three times daily for first 7 days, then 534 mg three times daily for 7 days, then maintenance 801 mg three times daily.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Terminal elimination half-life: ~2.5 hours (range 1.5–3.5 h); clinical context: no accumulation with twice-daily dosing; steady-state reached within 2–3 days.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Primarily hepatic metabolism via CYP1A2, with minor contributions from other CYP enzymes (CYP2C9, CYP2C19, CYP2D6, CYP2E1).
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Renal: ~80% (mostly as unchanged drug and metabolites); fecal: ~20%.
Low protein binding; 0–11% bound, primarily to albumin.
~60–70% bound to plasma proteins (primarily albumin).
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Vd: ~1 L/kg (range 0.8–1.2 L/kg); clinical meaning: extensive tissue distribution.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
Oral: ~80–85% (high bioavailability with minimal first-pass metabolism).
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
Contraindicated in GFR < 30 m L/min. For GFR 30-50 m L/min: reduce to 267 mg three times daily; monitor for adverse effects. No adjustment for GFR > 50 m L/min.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: contraindicated (insufficient data). Child-Pugh Class C: contraindicated.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Not approved for pediatric patients; safety and efficacy not established. No weight-based dosing guidelines available.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
No specific dose adjustment required; use caution due to potential increased sensitivity and higher incidence of renal impairment. Monitor renal function and gastrointestinal tolerability.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
No FDA black box warnings.
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hepatotoxicity: Elevations in liver enzymes and potential drug-induced liver injury; monitor LFTs regularly.,Photosensitivity: Avoid sun exposure; use broad-spectrum sunscreen.,Gastrointestinal effects: Nausea, diarrhea, dyspepsia; may require dose adjustment.,Drug interactions: Coadministration with strong CYP1A2 inhibitors (e.g., fluvoxamine) increases pirfenidone exposure; use with caution.,Smoking: Tobacco smoking induces CYP1A2, reducing pirfenidone exposure; advise smoking cessation.
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
Severe hepatic impairment (Child-Pugh Class C),History of hypersensitivity to pirfenidone or any excipient,Coadministration with strong CYP1A2 inhibitors (e.g., fluvoxamine) due to potential toxicity
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Avoid grapefruit juice (CYP3A4 interaction). Take with food to minimize GI upset. No other significant food interactions.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Pirfenidone is classified as FDA Pregnancy Category C. In animal studies, it caused fetal toxicity (reduced fetal weight, increased skeletal variations) at doses below human exposure. There are no adequate and well-controlled studies in pregnant women. The risk of major birth defects is unknown; use only if potential benefit justifies potential risk to the fetus. First trimester: potential for teratogenicity. Second and third trimester: possible fetal toxicity from maternal exposure.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
It is unknown if pirfenidone is excreted in human breast milk. The M/P ratio has not been determined. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for at least 2 weeks after the last dose.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
No specific dosing adjustments for pregnancy have been established. Due to changes in volume of distribution and renal clearance during pregnancy, therapeutic drug monitoring is not possible. Use lowest effective dose if absolutely necessary.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
Monitor liver function tests monthly for first 6 months, then every 3 months. Avoid use in moderate to severe hepatic impairment (Child-Pugh B/C). Photosensitivity is common; advise sun avoidance and broad-spectrum sunscreen. May cause gastrointestinal issues; take with food. Dose reduction required with strong CYP1A2 inhibitors (e.g., fluvoxamine). Smoking induces CYP1A2 and reduces exposure.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
Take with food to reduce stomach upset.,Avoid sun exposure; use sunscreen and protective clothing.,Report any signs of liver problems: jaundice, dark urine, abdominal pain.,Do not smoke while taking this medication.,Avoid grapefruit juice.,Complete blood tests as scheduled.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Pirfenidone, an antifibrotic agent used for idiopathic pulmonary fibrosis, may reduce the vasodilatory efficacy of alprostadil, a prostaglandin E1 analog. This interaction likely results from pirfenidone-induced downregulation of prostaglandin receptors or modulation of cyclic AMP signaling pathways, leading to diminished smooth muscle relaxation and reduced therapeutic response to alprostadil. Consequently, patients may experience suboptimal vasodilation, potentially compromising treatment for conditions like erectile dysfunction or peripheral arterial disease."
"Pirfenidone, an antifibrotic agent, may reduce the ocular hypotensive efficacy of bimatoprost, a prostaglandin analog used for glaucoma. This interaction is postulated to occur via pirfenidone's inhibitory effects on prostaglandin synthesis or signaling pathways, potentially attenuating bimatoprost-mediated enhancement of uveoscleral outflow. Clinically, patients may experience inadequate intraocular pressure (IOP) reduction, increasing the risk of glaucoma progression."
"Pindolol, a non-selective beta-blocker with intrinsic sympathomimetic activity, may antagonize the vasodilatory effects of pirfenidone, an antifibrotic agent known to reduce systemic vascular resistance. This pharmacodynamic interaction can blunt the antihypertensive efficacy of pirfenidone, potentially leading to inadequate blood pressure control in patients with pulmonary fibrosis and concurrent hypertension. Clinically, this may necessitate dose adjustments or alternative therapies to maintain optimal cardiovascular outcomes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs PIRFENIDONE, answered by our medical review team.
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. PIRFENIDONE is a Antifibrotic Agent that works by Pirfenidone is a pyridone derivative that inhibits TGF-β1-mediated collagen synthesis, reduces fibroblast proliferation, and downregulates the production of pro-inflammatory cytokines (e.g., TNF-α, IL-1β) and growth factors. Its exact mechanism in idiopathic pulmonary fibrosis (IPF) is not fully elucidated, but it is thought to exert antifibrotic and anti-inflammatory effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and PIRFENIDONE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. The standard adult dose of PIRFENIDONE is: 801 mg orally three times daily with food, total daily dose 2403 mg. Starting dose: 267 mg three times daily for first 7 days, then 534 mg three times daily for 7 days, then maintenance 801 mg three times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and PIRFENIDONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. PIRFENIDONE is classified as Category C. Pirfenidone is classified as FDA Pregnancy Category C. In animal studies, it caused fetal toxicity (reduced fetal weight, increased skeletal variations) at doses below human exposu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.